11C-LY2428703, a positron emission tomographic radioligand for the metabotropic glutamate receptor 1, is unsuitable for imaging in monkey and human brains by Paolo Zanotti-Fregonara et al.
Zanotti-Fregonara et al. EJNMMI Research 2013, 3:47
http://www.ejnmmires.com/content/3/1/47ORIGINAL RESEARCH Open Access11C-LY2428703, a positron emission tomographic
radioligand for the metabotropic glutamate
receptor 1, is unsuitable for imaging in monkey
and human brains
Paolo Zanotti-Fregonara1, Vanessa N Barth2, Sami S Zoghbi1, Jeih-San Liow1, Eric Nisenbaum2, Edward Siuda2,
Robert L Gladding1, Denise Rallis-Frutos1, Cheryl Morse1, Johannes Tauscher2, Victor W Pike1 and Robert B Innis1*Abstract
Background: A recent study from our laboratory demonstrated that 11C-LY2428703, a new positron emission
tomographic radioligand for metabotropic glutamate receptor 1 (mGluR1), has promising in vitro properties and
excellent in vivo performance for imaging rat brain. The present study evaluated 11C-LY2428703 for imaging
mGluR1 in monkey and human brains.
Methods: Rhesus monkeys were imaged at baseline and after administration of an mGluR1 blocking agent to
calculate nonspecific binding, as well as after the administration of permeability glycoprotein (P-gp) and breast
cancer resistance protein (BCRP) blockers to assess whether 11C-LY2428703 is a substrate for efflux transporters at
the blood–brain barrier. Human imaging was performed at baseline in three healthy volunteers, and arterial input
function was measured.
Results: Overall brain uptake was low in monkeys, though slightly higher in the cerebellum, where mGluR1s are
concentrated. However, the uptake was not clearly displaceable in the scans after mGluR1 blockade. Brain
penetration of the ligand did not increase after P-gp and BCRP blockade. Brain uptake was similarly low in all
human subjects (mean VT with a two-tissue compartment model, 0.093 ± 0.012 mL/cm
3) and for all regions,
including the cerebellum.
Conclusions: Despite promising in vitro and in vivo results in rodents, 11C-LY2428703 was unsuitable for imaging
mGluR1s in monkey or human brain because of low brain uptake, which was likely caused by high binding to
plasma proteins.
Keywords: mGluR1, PET, Kinetic modeling, DosimetryBackground
Metabotropic glutamate receptors 1 (mGluR1s) are G-
coupled receptors that regulate several brain functions,
including synaptic transmission and plasticity and ce-
llular excitability, and are potentially interesting drug
targets [1]. However, the development of mGluR1
radioligands for positron emission tomography (PET)
has been challenging. Successful tracers should have* Correspondence: innisr@mail.nih.gov
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reproduction in any medium, provided the orighigh affinity for mGluR1 but not significantly bind to
other receptors, particularly the structurally similar
mGluR5. Although several potential mGluR1 PET
radioligands have been described [2-8], only two [8,9]
have proven successful for imaging nonhuman primates,
and none have been tested in humans.
Our laboratory recently described a new 11C-labeled
mGluR1 antagonist - 11C-LY2428703 - with very promis-
ing characteristics. From an in vitro perspective,
LY2428703 has high affinity for human mGluR1s; after a
competition binding assay with 3H-LSN456066, Ki was
2.7 ± 0.5 nM for males and 1.4 ± 0.4 nM for females. Iner. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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homogenates displaceable only by mGluR1 antagonists
and no significant affinity for other human mGluRs [10].
An in vivo PET imaging study of rodents expanded this
favorable profile; indeed, that study found a large spe-
cific and displaceable signal in rat cerebellum, insig-
nificant in vivo binding to mGluR5, and negligible
accumulation of radiometabolites in brain. In addition,
LY2428703 was not a substrate for efflux transporters at
the blood–brain barrier, as assessed in genetic knockout
mice for ABCB1 (permeability glycoprotein (P-gp)) and
ABCG2 (breast cancer resistance protein (BCRP)) [10].
This study sought to determine whether 11C-LY2428703
could image and quantify mGluR1s in monkey and human
brains in a manner similar to its demonstrated ability to
do so in rodent brain. To answer this question, we intra-
venously injected 11C-LY2428703 into rhesus monkeys
and healthy humans and quantified brain uptake relative
to the delivery of radioligand to the brain via arterial
plasma (i.e., using compartmental modeling). We also ex-
amined factors known to affect the utility of radioligands
for brain imaging: blockade of entry into brain by efflux
transporters at the blood–brain barrier, the density of the
target (mGluR1) in brain, the affinity of 11C-LY2428703




11C-LY2428703 was synthesized as previously described
[10] and according to our Investigational New Drug Ap-
plication #112,494, submitted to the US Food and Drug
Administration. The radioligand was obtained in high
radiochemical purity (>99%) and specific activity (spe-
cific activity at injection is reported below). Labeling was
done with 11C, because it does not modify the basic
structure of the molecule.
Saturation binding assay
P2 membrane fractions were prepared from the cerebella
of male Sprague–Dawley rats (n = 3), male rhesus mon-
keys (n = 3), and female humans (n = 4). For saturation
analyses, 100 μg of cerebellar membrane protein and in-
creasing concentrations of [3H]LY456066 [11] were
added to quadruplicate wells in the presence of binding
buffer (10 mM K2HPO4, 1.2 mM KH2PO4, 100 mM KCl,
0.1% DMSO, 0.05% ethanol and 0.1% BSA, pH 7.6).
Nonspecific binding was defined by heterologous dis-
placement of 1 μM LY480084 (mGlu1 antagonist) in
select wells. Plates were incubated on ice for 75 min and
membranes harvested on 0.3% polyethylenimine pre-
treated Wallac filter mats using a Tomtec Harvester
MachII (Tomtec, Hamden, CT, USA). Dissociation con-
stant (KD) and receptor density (Bmax) values wereobtained in GraphPad Prism using standard nonlinear
one-site binding equations. Data are presented as mean
± SEM (n = 3 to 4); one-way analysis of variance
followed by Tukey's post hoc test.
Radiochromatographic analyses
Plasma analyses were performed on a reverse-phase
chromatography C18 column (Novapak, 4 μm, 100 × 8
mm, Waters Corp. Milford, MA, USA) using Radial-Pak®
compression module RCM-100 with a sentry pre-
column. Human plasma analyses were performed with a
mobile phase of MeOH/H2O/Et3N, 65:15:0.1 by volume,
at a flow rate of 2.5 mL/min; nonhuman primate plasma
samples were analyzed with a mobile phase of MeOH/
H2O/Et3N, 72.5:27.5:0.1 by volume, at a flow rate of
1.5 mL/min. To compare the outcome from both systems,
elution volume is reported rather than retention time.
In vitro stability of 11C-LY2428703 in human and
nonhuman primate blood
Nonradioactive anticoagulated blood was obtained on
the day of study from either human or nonhuman pri-
mates. Aliquots of 11C-LY2428703 (about 150 kBq) were
added to 0.5 mL of whole blood or 0.5 mL of plasma.
Samples were incubated at room temperature for
30 min, after which either 450 μL of the radioactive
plasma was added to 720 μL of acetonitrile or 200 μL of
the radioactive whole blood was added to 300 μL of
water. The tube containing the blood suspension was
shaken well to mix and lyse the blood cells. Seven hun-
dred and twenty microliters of acetonitrile was subse-
quently added and mixed well to precipitate the
proteins, followed by 100 μL of water, which was again
re-mixed. Radioactivity in the tubes was measured in a
gamma counter and then centrifuged at 10,000×g for 1
min. The clear supernatant liquid was injected into the
high-performance liquid chromatography (HPLC) column
and the precipitate counted to calculate the recovery of
radioactivity into the acetonitrile.
The stability of the radioligand in whole blood or
plasma was calculated as the ratio of the HPLC % com-
position of samples divided by the radiochemical purity
of the radioligand.
Radiometabolites of 11C-LY2428703 in human and
nonhuman primate plasma in vivo
Arterial plasma was analyzed as previously described
[12]. Briefly, after 11C-LY2428703 injection into either
human or nonhuman primate, the input function was
determined by periodically drawing anticoagulated blood
samples. Blood aliquots were removed so that the
γ-counter could provide information necessary for vas-
cular correction. The remaining blood was then
centrifuged, and plasma (450 μL) aliquots were removed
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rier LY2428703. The samples were mixed well, 100 μL
water aliquots were added, and then, the sample was fur-
ther mixed. The samples were counted in the γ-counter
and centrifuged at 10,000×g for 1 min. The clear super-
natant liquids were injected onto the radio-HPLC as de-
scribed above. The precipitates were then counted for
radioactivity to allow the calculation of the efficiency of
recovery of radioactivity in the acetonitrile. Human
plasma samples were separated with a mobile phase of
higher polarity (MeOH/H2O/Et3N, 65:15:0.1 by volume)
to ensure that the parent radiochromatographic peak
comprised a single radiochemical species.
Plasma free fraction
The plasma free fraction (fp) of
11C-LY2428703 was
measured by ultrafiltration through membrane filters
(Centrifree; Millipore, Billerica, MA, USA) as previously
described [13]. Briefly, about 740 kBq of 11C-LY2428703
(approximately 5 μL) was added to 650 μL of plasma.
The mixture was incubated at room temperature for 10
min and then processed as described previously [13].
When radioactivities for the filter components were
high, they were allowed to decay until they were within
the optimal range of the γ-counter. Determining the free
fraction during preblocking was done by drawing blood
samples after the preblocking treatments were initiated
but immediately before administering the radioligand.
Monkey studies
Four male rhesus monkeys (Macaca mulatta, 11.7 ±
2.9 kg) were imaged in 13 PET scans. Seven scans were
performed at baseline, three scans were performed after
receptor blocking to calculate nondisplaceable uptake
(VND), and three scans were performed after blockade of
the efflux transporters at the blood–brain barrier. Recep-
tors were blocked by mixing 11C-LY2428703 with an
mGluR1 antagonist - either nonradioactive LY2428703
(2.0 mg/kg) or LY2332084 (0.5 mg/kg) - in the same syr-
inge. Efflux transporters were blocked in two scans by
injecting DCPQ, which selectively blocks the efflux trans-
porter ABCB1 (P-gp), and in one scan by injecting
elacridar, which blocks both ABCB1 (P-gp) and ABCG2
(BCRP).
All studies were conducted in accordance with the
National Institutes of Health Guide for Care and Use of
Laboratory Animals.
PET scans
PET images were acquired using either the high-
resolution research tomograph (HRRT) or the FOCUS
220 scanner (Siemens/CPS, Knoxville, TN, USA) for 120
min in 33 frames, with frame durations ranging from 30
s to 5 min, and correcting for attenuation and scatter.About 2 h before the PET scan, anesthesia was initiated
with ketamine (10 mg/kg IM) and then maintained with
1% to 3% isoflurane. Electrocardiograph, body tem-
perature, heart rate, and respiration rate were measured
throughout the experiment. At baseline, the injected ac-
tivity was 210 ± 51 MBq (specific activity at time of in-
jection 43.2 ± 25.6 GBq/μmol, mass dose 6.9 ± 4.7 nmol
or 0.62 ± 0.35 nmol/kg). Tissue time-activity curves
were obtained from semi-automatic regions of interest
encompassing the whole cerebellum and the rest of the
brain. Brain uptake was expressed as standardized up-
take value (SUV). Arterial input function was obtained
for eight scans: four at baseline, two after blocking with
nonradioactive LY2428703, one after blocking with
DCPQ, and one after blocking with elacridar. Blood
samples (0.5 mL each) were drawn through a port
connected to the femoral artery at 15-s intervals until
2 min, followed by 1-mL samples at 3, 5, 10, 30, 60, 90,
and 120 min. The plasma time-activity curve was
corrected for the fraction of unchanged radioligand fol-
lowing the procedure detailed above.
To assess the effects of blocking agents on the fP of
11C-LY2428703, fP was measured in three monkeys both
at baseline and after blockade. The first monkey was
blocked with cold LY2428703 and fP was measured
2.5 min after blocker injection (which corresponds to
the maximal concentration in plasma of LY2428703),
and again at 40 min. The other two monkeys were
blocked with DCPQ and elacridar, respectively.
Whole-body biodistribution and radiation dosimetry
Two male rhesus monkeys (14.1 and 19.9 kg) were
scanned after intravenous injection of 318 and 274 MBq
of 11C-LY2428703, respectively. Dynamic two-dimensional
scans were acquired on the GE Advance tomograph
(GE Medical Systems, Milwaukee, WI, USA) in five bed
positions of the body (head to upper thigh), with frames
of increasing duration (15 s to 4 min) for a total scan
time of up to 115 min.
Images were analyzed by placing regions of interest on
the dynamic tomographic images. Regions were drawn
in identifiable source organs: brain, heart, lungs, liver,
spleen, gallbladder, kidneys, lumbar vertebrae, small in-
testine, testes, and urinary bladder. Because the images
did not include the body below mid-thigh, organ uptake
was corrected for this recovery. The mean recovery of
activity in the body above the thigh measured by PET
was 85.6% of the injected activity measured by a dose
calibrator. This recovered total activity in the body was
used as the new injected activity for each scan.
At each time point, the activity measured within the
organs was converted into the fraction of the injected
dose by dividing the organ activities by the recovered
injected activity. The area under the curve (AUC) of
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until acquisition ended. The area under the curve after
the acquisition of the last image (i.e., to infinity) was cal-
culated by assuming that the decline in radioactivity
after this time point occurred only via physical decay,
without any further biological clearance.
Residence times from the monkeys were converted
into corresponding human values by multiplying with a
factor to scale organ and body weights: (bm/om) × (oh/bh),
where bm and bh are the body weights of monkey and
human, respectively, and om and oh are the organ weights
of monkey and human, respectively.
Radiation absorbed doses were calculated from the
residence times for each source organ. We used the
model for a 70-kg adult male in the OLINDA/EXM
computer program [14].Human studies
Three healthy females participated in the study (29 ±
2-year old, 69 ± 13 kg). All were free from current medical
and psychiatric illnesses, as assessed by medical history,
physical examination, electrocardiogram, urinalysis in-
cluding drug screening, and blood tests (complete blood
count, serum chemistries, thyroid function test, and anti-
body screening for syphilis, HIV, and hepatitis B). The
National Institutes of Health Central Nervous System In-
stitutional Review Board approved the protocols and the
consent forms. Written informed consent was obtained
from all subjects.PET scans
PET images were acquired using the GE Advance
scanner (GE Healthcare, Milwaukee, WI, USA) for 120
min. An 8-min 68Ge transmission scan was obtained
before the injection of the radiotracer for attenuation
correction. The mean injected activity was 328 ±
12 MBq. The specific activity at the time of injection
was 87.2 ± 34.7 GBq/μmol, which corresponded to 5.5 ±
2.3 nmol (0.082 ± 0.037 nmol/kg) of carrier. Blood sam-
ples (1 mL each) were drawn from the radial artery at 15-s
intervals until 150 s, followed by 3-mL samples at 3, 4,
6, 8, 10, 15, 20, 30, 40, and 50 min, and 4.5 mL at 60, 75,
90, and 120 min. The unchanged parent fraction in
plasma and fP of
11C-LY2428703 were determined as de-
scribed above.Table 1 In vitro results (Bmax and KD in the cerebellar tissue a
Bmax (nM) KD (nM)
Rats 167 ± 24 (3) 6.6 ± 0.3 (3)
Monkeys 120 ± 8.6 (3) 6.6 ± 0.5 (3)
Humans 186 ± 11.6 (4)* 11.0 ± 1.6 (4)
n in parentheses. *p < 0.05 monkey vs. human. aTaken from [10].Magnetic resonance imaging
To identify brain regions, magnetic resonance (MR)
images were obtained using a 3-T GE Signa device (GE
Healthcare, Milwaukee, WI, USA). T1-weighted struc-
tural images were acquired with a voxel size of 0.86 mm ×
0.86 mm × 1.2 mm. The image acquisition sequences were
the time of repetition (7.3 ms), echo time length (2.8 ms),
and flip angle (6°).Image analysis
The average PET image created from all frames was first
coregistered to the individual MR image. Then, both MR
and all PET images were spatially normalized to a stand-
ard anatomic orientation (Montreal Neurological Insti-
tute (MNI) space) based on transformation parameters
from the MR images. A volume-of-interest template [15]
as implemented in PMOD (PMOD Technologies Ltd,
Zurich, Switzerland) was used to obtain brain time-
activity curves.Kinetic analysis
Volumes of distribution (VT) were obtained by nonlinear
compartmental analysis. Goodness-of-fit by nonlinear
least squares analysis was evaluated using the Akaike In-
formation Criterion (AIC) and Model Selection Criterion
(MSC). The most appropriate model is that with the
smallest AIC and the largest MSC score. Goodness-of-fit
by the compartment models was compared with F statis-
tics [16]. A value of P < 0.05 was considered significant
for F statistics. The identifiability of kinetic variables was
calculated as standard error obtained from the diagonal
of the covariance matrix [17] and expressed as a per-
centage of the rate constant.Results
Saturation binding assay
Human cerebellum had a Bmax value (186 nM) higher
than that of the cerebellum of rats (167 nM) and mon-
keys (120 nM). However, humans also had a higher KD
value (11.1 nM) compared to rats and monkeys (6.6 nM
for both species). Therefore, humans displayed a Bmax/KD
ratio (16.9) lower than that of rats (25.3) but similar to
that of monkeys (18.2) (Table 1).nd plasma free fraction) for rats, monkeys, and humans
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Pharmacological effects
11C-LY2428703 injection caused no significant changes
in pulse, respiratory rate, or electrocardiogram.
Plasma analysis
The radioligand was completely stable at room tem-
perature in monkey whole blood and plasma. After intra-
venous injection, the concentration of 11C-LY2428703
peaked at 1 to 1.5 min and then declined following a curve
that was well fit with a tri-exponential function. At base-
line, the parent became 50% of the total plasma radioactiv-
ity between 7 and 60 min (n = 4) after injection. Two
radiometabolites, less lipophilic than 11C-LY2428703, were
detected with retention volume at 3.2 ± 0.7 mL and 5.2 ±
1.7 mL while the parent's retention volume was 7.2 ±
1.6 mL (n = 120). The average fp value from three base-
line monkeys was 0.884 ± 0.37%.
Brain images
Brain uptake was low, but the cerebellum (the region
with the highest density of mGluR1s) had a visibly,
though slightly, greater uptake than the rest of the brain.
The peak uptake in the cerebellum was 3.1 ± 1.4 SUV at
approximately 2 min and decreased to 50% of that value
at about 20 min. The peak uptake in cerebellum was
about 50% higher than that in forebrain (2.2 ± 0.8 SUV
at approximately 2 min). However, after mGluR1 block-
ade, peak uptake increased, rather than decreased, both
in cerebellum (4.9 ± 0.8 SUV) and in forebrain (3.6 ± 1.9
SUV). This increase was not explained by an increase in
the arterial plasma input functions or by an increase of
ƒp. In fact, in the monkey that underwent an mGluR1
blocked scan with nonradioactive LY2428703, fp values
were lower after blockade (1.12 ± 0.18%, n = 4, at 2.5
min; and 0.89 ± 0.14%, n = 4, at 40 min) than at baseline
(1.25 ± 0.12%, n = 4).
Kinetic analysis
Although the receptor blocking studies showed no dis-
placeable (i.e., no specific) binding based on peak uptake,
the images were more accurately quantified using the
entire scan duration and correcting for delivery of
radioligand to brain, namely, compartmental modeling.
Nevertheless, using a two-tissue compartment model
(which showed a better goodness-of-fit than one-
compartmental model), we found no evidence of specific
binding based on the blockade studies. The mean VT
value in the baseline scans was 3.5 ± 1.0 mL/cm3, but VND
calculated from mGluR1 blocking studies was unexpect-
edly higher than the baseline value (4.4 ± 2.9 mL/cm3).
Low brain uptake of 11C-LY2428703 was not caused
by the radioligand being a substrate at the blood brain
barrier for the two most prevalent ABC transporters:P-gp and BCRP. In fact, blocking the blood–brain bar-
rier efflux transporters did not increase brain uptake.
For DCPQ, which selectively blocks P-gp, the VT in
cerebellum was 4.4 mL/cm3 at baseline and 4.2 mL/cm3
after blockade. For elacridar, which blocks both P-gp
and BCRP,VT in cerebellum was 2.0 mL/cm
3 at baseline
and decreased to 0.8 mL/cm3 after blockade. Pharmaco-
logic doses of these two blocking agents might have
displaced radioligand bound to plasma proteins, thus in-
directly increasing brain uptake, but such was not the
case. In the DCPQ blocking experiments, fp was similar
at baseline (1.074% ± 0.15%, n = 3) and after blockade
(1.100% ± 0.04%, n = 3) scans. For the elacridar blocking
experiment, where VT decreased after blocking, fp actu-
ally doubled from baseline (0.456% ± 0.05%, n = 3) to
post-blockade (0.912% ± 0.05%, n = 3).
Whole-body biodistribution and radiation dosimetry
Intravenous 11C-LY2428703 injection caused no signifi-
cant changes in electrocardiogram, heart, or respiration
rates from baseline values. 11C-LY2428703 appeared to
be excreted through both urine and bile in monkey, as
there was activity in the urinary bladder and transient
bile in the small intestine.
The liver had the highest uptake of 11C-LY2428703,
with an average peak of approximately 12 SUV injected
activity at about 5 min post-injection. Activity in the
gallbladder progressively increased throughout the scan.
The other organs exhibited a lower uptake of radioactiv-
ity, generally between 2 and 5 SUV. Radiation-absorbed
doses were highest in the testes (13.7 μSv/MBq), the
liver (9.9 μSv/MBq), and the heart wall (8.2 μSv/MBq).
Lower doses (always less than 7 μSv/MBq) were esti-
mated for the other organs (data not shown). The final
effective dose was 5.8 μSv/MBq.
Human studies
Pharmacological effects
Injection of 11C-LY2428703 caused no pharmacological
effects as assessed by vital signs, electrocardiogram, and
laboratory testing as well as verbal reports from all three
subjects.
Plasma analysis
The radioligand was quite stable in vitro in whole blood
at room temperature for 30 min. Tracer stability was
99.5 ± 1.1% (n = 3) in whole blood and 99.4 ± 1.4%
(n = 3) in plasma. In vivo, only traces of radiometabolites
were detected in plasma during the entire 2-h period of
the imaging study so that the parent radioligand
remained close to 99% total blood radioactivity. Human
plasma samples were analyzed under chromatographic
conditions where the 11C-LY2428703 was retained on
the column for an even longer period of time than for




















Figure 2 Whole-brain time-activity curves without (black-filled
circle, ●) and with (white-filled circle, ○) vascular correction. The
measured whole blood radioactivity was used for vascular
correction, assuming that blood constitutes 5% brain volume.
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ration from any potential plasma radiometabolites. This
does not necessarily mean that 11C-LY2428703 was
not metabolized but rather that the fate of the
radiometabolites is unknown. For example, the absence
of radiometabolites from human plasma might be due to
organ entrapment. The concentration of 11C-LY2428703
peaked at 1.5 ± 0 min (33 ± 5 SUV) and then slowly
declined following a curve that was well fit as a
tri-exponential function. The parent radioactivity eluted
at 6.6 ± 1.5 mL (n = 64). The ƒp levels were 0.094 ±
0.01% (n = 3).
Brain images
After 11C-LY2428703 injection, the brain was poorly vi-
sualized in all subjects (Figure 1), with a peak uptake of
1.14 ± 0.18 SUV that occurred at 1.3 ± 0 min after injec-
tion, followed by a gradual wash-out. Notably, the brain
peak uptake occurred before the arterial peak in the ra-
dial artery, suggesting that the peak in the brain was
mostly due to vascular activity. Indeed, when the brain
time-activity curves were corrected for the vascular
component, the peak disappeared (Figure 2).
Brain activity decreased to 50% of the peak after an
average of 20 min. Although a slightly higher uptake in
the cerebellar cortex was observed (Figure 1), the uptake
was fairly homogeneous throughout the brain. All brain
activity was likely due to the parent compound, as only
negligible amount of radiometabolites were detected in
plasma (approximately 1% at 2 h, see above).
Kinetic analysis
Although brain uptake was low, we wondered whether
kinetic analysis of the brain and plasma data would sug-
gest any specific binding in the brain. In fact, VT valuesFigure 1 Transverse brain slices from a healthy volunteer at the
level of the cerebellum (left) and frontal cortex (right). Images
are the sum of all PET frames coregistered to the individual MRI. The
foci of high 11C-LY2428703 uptake were due to vascular activity
(carotids and posterior venous sinuses) at early time points. Vascular
activity was clearly visible on the final summed image because
uptake in the brain regions was negligible.with 2TCM were very low (<0.1 mL/cm3) and were simi-
lar across all brain regions, including the cerebellum
(Table 2).
Discussion
Our laboratory recently described 11C-LY2428703, a new
mGluR1 antagonist with promising characteristics based
on in vitro testing and on in vivo PET imaging of
rodents [10]. However, the present study found that
11C-LY2428703 cannot image or quantify mGluR1s in
monkey or human brain because of very low brain up-
take, largely caused by high binding of the radioligand to
plasma proteins.
In monkeys, the overall uptake was quite low, though
slightly higher in the cerebellum, where mGluR1s are
concentrated. Nevertheless, even in the cerebellum, the
uptake was not clearly blocked by pharmacological doses
of an mGluR1 antagonist.
Despite these poor results in monkeys, we decided to
test the tracer in humans for two reasons. First, our
in vitro analyses of cerebellar tissues showed that
humans had higher Bmax values (186 ± 11.6 nM) thanTable 2 Kinetic modeling results in humans using a
two-tissue compartment model
Compartmental distribution volume
Region VT (mL · cm
−3)
Frontal cortex 0.092 ± 0.016 (14.2%)
Temporal cortex 0.102 ± 0.010 (4.4%)
Parietal cortex 0.087 ± 0.011 (4.9%)
Caudate 0.086 ± 0.024 (22.6%)
Cerebellum 0.090 ± 0.010 (2.8%)
Representative brain regions from the three human subjects. Values are mean ± SD.
Standard errors are listed in parentheses and are expressed as percent (%) of the
variable itself.
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could have provided a larger signal in humans. Second,
results in monkeys do not always approximate those in
humans. For example, 18F-SP203, a radioligand for
mGluR5, displayed problematic characteristics in both
rodents and monkeys due to defluorination in the brain
and/or periphery [18]. Nevertheless, defluorination was
relatively low in humans, and brain distribution volume
could be robustly calculated with compartmental model-
ing [19]. In the present study, however, 11C-LY2428703
had low brain uptake in both humans and monkeys.
These disappointing results in human and nonhuman
primates were unexpected in light of the high in vitro
affinity of this ligand for human and monkey receptors
and the promising in vivo results in rats and mice [10].
Several factors may have contributed to these results:
(1) efflux transporters at the blood–brain barrier, (2) low
receptor density in humans, (3) lower in vivo binding
affinity compared to that measured in vitro, (4) low de-
livery of the radioligand to brain, and (5) low binding
potential in the brain. As discussed in greater detail
below, we think that the last two factors were the most
problematic.
Specifically, low brain penetration may have been due
to the activity of efflux transporters at the blood–brain
barrier. Whether 11C-LY2428703 is a substrate for these
transporters in humans is unknown. However, our previ-
ous in vitro analyses found that 11C-LY2428703 was not
a substrate for P-gp; in vivo imaging studies conducted
in knockout mice further found that 11C-LY2428703 was
not a substrate for either P-gp or BCRP [10]. In addition,
the current study showed that 11C-LY2428703 was not a
substrate for P-gp or BCRP in monkey based on
pharmacological blockade.
Another possible explanation is the differing receptor
density between rodents and primates. However, in the
present study, cerebellar Bmax values were slightly higher
in humans (186 ± 11.6) than in rats (167 ± 24) and mon-
keys (120 ± 8.6) (Table 1). Other published studies simi-
larly found higher Bmax for humans (82 ± 33 nM) than
for monkeys (53 ± 12 nM), although values for rats were
much higher (430.2 ± 204.2 nM) [8,20,21]. Moreover,
species differences may be responsible for alterations in
the structure of the receptor. However, this is unlikely toTable 3 Brain exposure for five different radioligands
11C-LY2428703 18F-FMPEP [22]
Target mGluR1 CB1
Brain peak SUV ~0.5 3 to 4
Exposure SUV (0 to 20) 202.2 47.8
fp % 0.094 0.63
Effective exposure (E × fp) 0.19 0.30be the reason for the poor imaging properties of 11C-
LY2428703 in primates. In fact, although in vitro KD
values are higher in humans (11.0 ± 1.6 nM), they are
very similar between monkeys (6.6 ± 0.5 nM) and rats
(6.6 ± 0.3 nM) (Table 1).
It is also important to note that binding affinity may
change between in vitro and in vivo conditions, for
example, as a consequence of temperature. Huang and
colleagues observed a fourfold decrease in the binding
affinities of their mGluR1 tracers when the temperature
of the binding assay was raised from 4°C to 37°C [21].
However, for this explanation to apply to 11C-LY2428703,
the difference between in vitro and in vivo affinities for
mGluR1 would have varied across species. That is, the
in vitro affinity in humans (about 2 nM) was similar to
that in rats (0.6 nM), although PET imaging was success-
ful only in rats.
Another complicating factor is low delivery to brain
(i.e., low drug exposure), which may have cause low
brain uptake. We compared five different radioligands
from previous studies with regard to exposure to brain
(Table 3) and measured the area under the curve of
plasma concentration vs. time from 0 to 20 min. To de-
termine whether decreased exposure was due to rapid
clearance from plasma or low free fraction, we calculated
AUC0 to 20 for the total concentration of radioligand in
plasma as well as a variable we termed ‘effective expos-
ure,’ i.e., fp × AUC0 to 20. The effective exposure was thus
named because only the free concentration of drug can
cross the blood–brain barrier. 11C-LY2428703 had the
highest exposure value among the tracers tested. This
high exposure was due to the slow wash-out of the
tracer from the vascular compartment and to negligible
metabolism in plasma, that is, parent radioligand repre-
sented 99% of plasma radioactivity even at the end of
the 2-h scanning session. Interestingly, due to its very
low fp (0.094%),
11C-LY2428703 displayed the lowest
effective exposure among the five tested ligands. Thus,
high binding to plasma proteins (i.e., low values of fP)
markedly decreased effective exposure of the radioligand
to brain.
Finally, with regard to binding potential in the brain,
we assumed that equilibrium or near-equilibrium bind-
ing conditions existed in the brain at the time of peak18F-SP203 [19] 11C-(R)-rolipram [23] 11C-NOP1A [24]
mGluR5 PDE4 NOP
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http://www.ejnmmires.com/content/3/1/47brain uptake. Following the Michaelis-Menten equation
for receptor binding:
B ¼ F  Bmax= KD þ Fð Þ ð1Þ
where B is the specifically bound ligand and F its free
concentration. Because F << KD in this PET study using
tracer doses of radioligand,
B ¼ F  Bmax=KDð Þ ¼ F  Bmax  affinity
¼ F  BP ð2Þ
Following the consensus nomenclature [25], F = CFND.
Furthermore, CFND is itself linearly related to fp, as
shown below:
At equilibrium;CFND ¼ CFP ð3Þ
where CFND is the concentration of the free ligand in the
nondisplaceable compartment and CFP is the concentra-
tion of free ligand in plasma.
CFND ¼ f ND  CND and CFP ¼ f p  CP ð4Þ
CFND ¼ f p  CP or CFND α f p ð5Þ
Thus, we were able to calculate effective BP (which
corrects BP for plasma free fraction) as fp × Bmax/KD,
which equals the specific volume of distribution VS. Not-
ably, monkeys (0.161) had a tenfold higher effective BP
than humans (0.016). In fact, although Bmax/KD for mon-
keys (18.2) was similar to that for humans (16.9), the fp
value for monkeys (0.884%) was much higher than that
for humans (0.094%). Due to their higher fp (2.7%), rats
had the highest effective binding potential (0.683) of the
three species (Table 1).
The terms effective exposure and effective BP help
reinforce the fact that fp influences not only the amount
of radioligand exposed to the brain (and thus available
for uptake) but also the maximal amount of drug that
the brain can retain at equilibrium. Thus, the single
greatest limitation of 11C-LY2428703 may be excessive
binding to plasma proteins. Indeed, 11C-LY2428703 is
highly lipophilic: the measured LogD at room
temperature in octanol was 4.02 [10]. High lipophilicity
is associated with high binding to plasma proteins and
high nonspecific binding in brain [21,26]. The two
mGluR1 ligands that showed a high signal in the mon-
key brain, 18F-MK1312 [8] and 18F-FITM [5], displayed a
lower lipophilicity than our tracer (with LogD values of
2.3 and 1.5, respectively).
Although the terms effective exposure and effective
binding potential demonstrate the dual roles of plasma
protein binding, it is important to note all three factors
that affect specific binding in brain: F, Bmax, and KD
(Eq. 2). Thus, an unusually low F (caused by low fp)could be compensated for by an unusually large Bmax or
by an unusually small KD (i.e., high affinity). Such is the
case for 18F-FMPEP-d2 binding to the cannabinoid CB1
receptor in brain (Table 3). This highly lipophilic
radioligand has an unusually low free fraction in plasma
(fp = 0.63%). Nevertheless, CB1 receptor density is very
high and among the most abundant G-protein coupled
receptors in mammalian brain [27]. Thus, 11C-LY2428703's
unusual property of high binding to plasma proteins
creates a reservoir of radioligand in plasma that restricts
delivery to and retention in the brain, ultimately impeding
its utility as a useful radioligand.
The present study also measured the dosimetry from
11C-LY2428703 in monkeys and extrapolated these mea-
surements to humans and obtained a final effective dose
of 5.8 μSv/MBq. This figure is well within the range of
values for 11C-labeled tracers [28]. Indeed, the range of
dosimetric results of 11C-tracers is uniform enough that
we question the utility of dosimetry studies in primates
and a fortiori in rodents. The radiation safety committee
of the NIH similarly endorses this point of view and
recently decided that animal dosimetry scans are not ne-
cessarily required before first-in-human injections of
new 11C-labeled tracers. It could further be argued that
even human dosimetry is unnecessary at the initial ex-
ploratory evaluation of a new tracer. As proposed by van
der Aart and colleagues, a standard conservative dosim-
etry value could be assigned to all new 11C-tracers [29].
A full dosimetry study would be performed later only if
the initial kinetic evaluation in the brain was favorable.
Conclusions
Despite very promising in vitro and in vivo results in
rodents, 11C-LY2428703 was unsuitable for imaging
mGluR1 in monkey or human brain, most likely because
of high binding to plasma proteins that restricted deli-
very to and retention in the brain.
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